Loading...

Vernalis

BST:BBP2
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BBP2
BST
£33M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The last earnings update was 196 days ago. More info.


Add to Portfolio Compare Print Invest
  • Vernalis has significant price volatility in the past 3 months.
BBP2 Share Price and Events
Price Volatility
BBP2
Industry
5yr Volatility vs Market

Value

 Is Vernalis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vernalis. This is due to cash flow or dividend data being unavailable. The share price is €0.069.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vernalis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vernalis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:BBP2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-12-31) in GBP £-0.09
AIM:VER Share Price ** AIM (2018-10-05) in GBP £0.06
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 31.83x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vernalis.

BST:BBP2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:VER Share Price ÷ EPS (both in GBP)

= 0.06 ÷ -0.09

-0.68x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vernalis is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Vernalis is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Vernalis's expected growth come at a high price?
Raw Data
BST:BBP2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.68x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.68x
Germany Market PEG Ratio Median Figure of 274 Publicly-Listed Companies 1.43x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vernalis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vernalis's assets?
Raw Data
BST:BBP2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-12-31) in GBP £0.09
AIM:VER Share Price * AIM (2018-10-05) in GBP £0.06
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.51x
Germany Market PB Ratio Median Figure of 579 Publicly-Listed Companies 1.95x
BST:BBP2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:VER Share Price ÷ Book Value per Share (both in GBP)

= 0.06 ÷ 0.09

0.71x

* Primary Listing of Vernalis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vernalis is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Vernalis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vernalis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vernalis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vernalis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.3%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vernalis expected to grow at an attractive rate?
  • Unable to compare Vernalis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vernalis's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Vernalis's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:BBP2 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.3%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:BBP2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:BBP2 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BST:BBP2 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2017-12-31 23 -22 -48
2017-09-30 22 -21 -35
2017-06-30 21 -20 -22
2017-03-31 17 -23 -20
2016-12-31 12 -25 -18
2016-09-30 12 -23 -16
2016-06-30 12 -21 -14
2015-12-31 14 -15 -14
2015-09-30 14 -11 -9
2015-06-30 14 -7 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vernalis is high growth as no earnings estimate data is available.
  • Unable to determine if Vernalis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:BBP2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Vernalis Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:BBP2 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BST:BBP2 Past Financials Data
Date (Data in GBP Millions) EPS *
2017-12-31 -0.09
2017-09-30 -0.07
2017-06-30 -0.04
2017-03-31 -0.04
2016-12-31 -0.04
2016-09-30 -0.03
2016-06-30 -0.03
2015-12-31 -0.03
2015-09-30 -0.02
2015-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vernalis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Vernalis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Vernalis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Vernalis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Vernalis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vernalis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vernalis performed over the past 5 years?

  • Vernalis's last earnings update was 196 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vernalis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vernalis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Vernalis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vernalis's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vernalis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vernalis Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:BBP2 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 22.74 -48.09 34.36 10.47
2017-09-30 22.02 -34.83 34.26 10.78
2017-06-30 21.30 -21.56 34.16 11.08
2017-03-31 16.59 -19.74 31.34 10.96
2016-12-31 11.87 -17.92 28.53 10.83
2016-09-30 12.15 -16.21 27.12 10.88
2016-06-30 12.43 -14.50 25.72 10.93
2015-12-31 14.10 -13.56 16.35 13.48
2015-09-30 13.88 -8.92 11.05 14.26
2015-06-30 13.66 -4.27 5.76 15.04
2014-12-31 12.27 -2.94 5.42 14.02
2014-09-30 12.67 -7.85 5.18 14.41
2014-06-30 13.06 -12.77 4.95 14.81
2014-03-31 13.66 -8.39 4.93 14.61
2013-12-31 14.26 -4.00 4.91 14.42
2013-09-30 15.28 -0.97 4.94 13.72
2013-06-30 16.30 2.06 4.98 13.03
2013-03-31 15.46 -1.59 5.12 13.00
2012-12-31 14.62 -5.24 5.25 12.98
2012-06-30 13.71 -5.07 5.03 13.41
2012-03-31 12.93 -6.98 4.93 13.51
2011-12-31 12.16 -8.88 4.83 13.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vernalis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vernalis has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vernalis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vernalis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vernalis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vernalis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vernalis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vernalis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vernalis's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vernalis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vernalis has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vernalis Company Filings, last reported 9 months ago.

BST:BBP2 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 45.94 0.00 46.02
2017-09-30 45.94 0.00 46.02
2017-06-30 82.78 0.00 61.26
2017-03-31 82.78 0.00 61.26
2016-12-31 92.43 0.00 74.18
2016-09-30 92.43 0.00 74.18
2016-06-30 102.73 0.00 84.02
2015-12-31 70.22 0.00 54.00
2015-09-30 70.22 0.00 54.00
2015-06-30 77.11 0.00 61.56
2014-12-31 80.18 0.00 70.75
2014-09-30 80.18 0.00 70.75
2014-06-30 78.05 0.00 70.34
2014-03-31 78.05 0.00 70.34
2013-12-31 82.24 0.00 76.94
2013-09-30 82.24 0.00 76.94
2013-06-30 90.00 0.00 85.66
2013-03-31 90.00 0.00 85.66
2012-12-31 85.46 0.00 81.56
2012-06-30 87.12 0.00 84.46
2012-03-31 87.12 0.00 84.46
2011-12-31 23.98 0.00 24.75
  • Vernalis has no debt.
  • Vernalis has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vernalis has sufficient cash runway for 2.6 years based on current financial obligations.
  • Vernalis has sufficient cash runway for more than 3 years if financial obligations continue to grow at historical rates of 25.9% each year.
X
Financial health checks
We assess Vernalis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vernalis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vernalis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vernalis dividends.
If you bought €2,000 of Vernalis shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vernalis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vernalis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:BBP2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:BBP2 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vernalis has not reported any payouts.
  • Unable to verify if Vernalis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vernalis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vernalis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vernalis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vernalis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vernalis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vernalis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ian Garland, image provided by Google.
Ian Garland
COMPENSATION £656,000
AGE 52
TENURE AS CEO 9.8 years
CEO Bio

Mr. Ian R. Garland has been the Chief Executive Officer of Vernalis plc since December 29, 2008. Mr. Garland serves as the Chief Operating Officer of UCB Pharma, Inc. He served as the Chief Executive Officer of Sanofi Pasteur Holding Limited from May 2007 to September 2008. Mr. Garland served as the Chief Financial Officer of Arrow Therapeutics Ltd from June 2004 to 2007. He served as the Chief Financial Officer of Amarin Corp. PLC since March 2003. Mr. Garland joined Amarin from Celltech Group PLC, the UK’s largest bio-pharmaceutical company, where he run US specialty pharmaceutical operations since 1999. He joined Celltech US in 1997 as Chief Financial Officer and from 1999 as Head of US operations. Mr. Garland served as a Finance Director of Pepsi Cola International in New York. He served as Chief Operating Officer of Celltech Manufacturing, Inc. From 1999 to 2003, he served as the President and Chief Operating Officer of Celltech Pharmaceuticals Inc and was responsible for all US activities, including marketing, manufacturing and supply chain management and US-based development and support functions. He served for seven years at KPMG in London specializing in pharmaceuticals. He has been an Executive Director of Sanofi Pasteur Holding Limited since May 8, 2007 and Vernalis plc since June 2009. Mr. Garland is a Member of Advisory Board of Bio Equity Risk Management. He is a Chartered Accountant.

CEO Compensation
  • Ian's compensation has been consistent with company performance over the past year.
  • Ian's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Vernalis management team in years:

10.8
Average Tenure
  • The average tenure for the Vernalis management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Ian Garland

TITLE
CEO & Executive Director
COMPENSATION
£656K
AGE
52
TENURE
9.8 yrs

David MacKney

TITLE
CFO & Executive Director
COMPENSATION
£463K
AGE
50
TENURE
9.7 yrs

Susan Wallcraft

TITLE
Group General Counsel & Company Secretary
TENURE
0.8 yrs

Joseph Canny

TITLE
Vice President of Marketing
TENURE
12.4 yrs

Donna Radzik

TITLE
Senior Vice President of Pharmaceutical Quality Operations

Jean Hubble

TITLE
Vice President of Medical Affairs
TENURE
11.8 yrs

Mike Wood

TITLE
Research Director
TENURE
14.7 yrs
Board of Directors Tenure

Average tenure and age of the Vernalis board of directors in years:

8.5
Average Tenure
52.5
Average Age
  • The tenure for the Vernalis board of directors is about average.
Board of Directors

Peter Fellner

TITLE
Non-Executive Chairman
COMPENSATION
£125K
AGE
75
TENURE
15.5 yrs

Ian Garland

TITLE
CEO & Executive Director
COMPENSATION
£656K
AGE
52
TENURE
9.8 yrs

David MacKney

TITLE
CFO & Executive Director
COMPENSATION
£463K
AGE
50
TENURE
9.7 yrs

Carol Ferguson

TITLE
Senior Independent Director
COMPENSATION
£53K
AGE
71
TENURE
7.3 yrs

Nigel Sheail

TITLE
Non-Executive Director
COMPENSATION
£40K
AGE
53
TENURE
7.2 yrs

Lisa Schoenberg

TITLE
Non-Executive Director
COMPENSATION
£40K
AGE
52
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
08. Oct 18 Sell Legal & General Investment Management Limited Company 05. Oct 18 05. Oct 18 -2,900,000 $-233,081.70
02. Oct 18 Sell Legal & General Investment Management Limited Company 01. Oct 18 01. Oct 18 -899,287 $-72,023.00
19. Sep 18 Sell Legal & General Investment Management Limited Company 18. Sep 18 18. Sep 18 -7,000,000 $-561,337.00
19. Sep 18 Buy Oddo Bhf Asset Management SAS Company 18. Sep 18 18. Sep 18 6,937,287 $556,307.98
10. Sep 18 Buy Oddo Bhf Asset Management SAS Company 07. Sep 18 07. Sep 18 462,713 $36,307.24
07. Sep 18 Buy Oddo Bhf Asset Management SAS Company 06. Sep 18 06. Sep 18 600,000 $47,043.60
03. Sep 18 Buy Oddo Bhf Asset Management SAS Company 31. Aug 18 31. Aug 18 84,150 $6,574.81
31. Aug 18 Buy Oddo Bhf Asset Management SAS Company 30. Aug 18 30. Aug 18 889,850 $69,616.52
29. Aug 18 Buy Oddo Bhf Asset Management SAS Company 28. Aug 18 28. Aug 18 26,000 $2,016.22
23. Aug 18 Buy Oddo Bhf Asset Management SAS Company 22. Aug 18 22. Aug 18 820,973 $63,795.35
21. Aug 18 Buy Oddo Bhf Asset Management SAS Company 20. Aug 18 20. Aug 18 165,000 $12,677.78
20. Aug 18 Buy Oddo Bhf Asset Management SAS Company 17. Aug 18 17. Aug 18 11,850,742 $908,501.58
20. Aug 18 Sell Legal & General Investment Management Limited Company 17. Aug 18 17. Aug 18 -10,339,265 $-792,653.44
17. Aug 18 Sell Legal & General Investment Management Limited Company 16. Aug 18 16. Aug 18 -100,000 $-7,738.80
08. May 18 Sell GAM Holding AG Company 17. Apr 18 17. Apr 18 -250,000 $-13,152.75
21. Mar 18 Sell GAM Holding AG Company 20. Mar 18 20. Mar 18 -250,000 $-11,543.25
20. Mar 18 Sell GAM Holding AG Company 19. Mar 18 19. Mar 18 -250,000 $-11,225.25
20. Mar 18 Sell GAM Holding AG Company 16. Mar 18 16. Mar 18 -4,500,000 $-214,614.00
X
Management checks
We assess Vernalis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vernalis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

Details
Name: Vernalis plc
BBP2
Exchange: BST
Founded: 1988
£37,144,816
526,986,000
Website: http://www.vernalis.com
Address: Vernalis plc
100 Berkshire Place,
Wharfedale Road,
Winnersh,
Berkshire, RG41 5RD,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM VER Ordinary Shares London Stock Exchange AIM Market GB GBP 02. Jul 1992
DB BBP2 Ordinary Shares Deutsche Boerse AG DE EUR 02. Jul 1992
BST BBP2 Ordinary Shares Boerse-Stuttgart DE EUR 02. Jul 1992
OTCPK VNLP.Y SPONSORE ADR NEW Pink Sheets LLC US USD 01. Jul 1992
Number of employees
Current staff
Staff numbers
115
Vernalis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/10 18:26
End of day share price update: 2018/10/05 00:00
Last estimates confirmation: 2017/09/12
Last earnings filing: 2018/03/28
Last earnings reported: 2017/12/31
Last annual earnings reported: 2017/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.